StageZero Life Sciences Ltd. (SZLSF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 1.8 Million USD | 32.73% |
| 2021 | 1.35 Million USD | -62.01% |
| 2020 | 3.57 Million USD | 45.17% |
| 2019 | 2.45 Million USD | -23.73% |
| 2018 | 3.22 Million USD | 103.55% |
| 2017 | 1.58 Million USD | -47.6% |
| 2016 | 3.02 Million USD | 128.78% |
| 2015 | 1.32 Million USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 261.4 Thousand USD | -93.94% |
| 2012 | 4.31 Million USD | 21.35% |
| 2011 | 3.55 Million USD | -8.25% |
| 2010 | 3.87 Million USD | 40.78% |
| 2009 | 2.75 Million USD | 66.61% |
| 2008 | 1.65 Million USD | -27.87% |
| 2007 | 2.29 Million USD | 2503.36% |
| 2006 | 87.97 Thousand USD | -57.77% |
| 2005 | 208.34 Thousand USD | -31.54% |
| 2004 | 304.32 Thousand USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.86 Million USD | 20.72% |
| 2024 Q1 | 1.72 Million USD | 0.0% |
| 2023 Q1 | 2 Million USD | 11.64% |
| 2023 Q2 | 1.48 Million USD | -26.27% |
| 2023 Q3 | 1.35 Million USD | -8.31% |
| 2022 Q2 | 1.38 Million USD | 6.2% |
| 2022 Q1 | 1.3 Million USD | -3.88% |
| 2022 FY | 1.8 Million USD | 32.73% |
| 2022 Q4 | 1.8 Million USD | 3.72% |
| 2022 Q3 | 1.73 Million USD | 25.36% |
| 2021 FY | 1.35 Million USD | -62.01% |
| 2021 Q4 | 1.35 Million USD | -3.6% |
| 2021 Q3 | 1.4 Million USD | -11.06% |
| 2021 Q2 | 1.58 Million USD | -18.61% |
| 2021 Q1 | 1.94 Million USD | -45.56% |
| 2020 Q4 | 3.57 Million USD | 5.15% |
| 2020 FY | 3.57 Million USD | 45.17% |
| 2020 Q1 | 2.65 Million USD | 7.84% |
| 2020 Q2 | 2.57 Million USD | -2.95% |
| 2020 Q3 | 3.39 Million USD | 31.91% |
| 2019 Q4 | 2.45 Million USD | -23.64% |
| 2019 Q2 | 3.74 Million USD | -13.44% |
| 2019 Q1 | 4.33 Million USD | 34.35% |
| 2019 Q3 | 3.22 Million USD | -14.11% |
| 2019 FY | 2.45 Million USD | -23.73% |
| 2018 Q4 | 3.22 Million USD | -10.54% |
| 2018 FY | 3.22 Million USD | 103.55% |
| 2018 Q1 | 2.08 Million USD | 31.82% |
| 2018 Q2 | 3.55 Million USD | 70.42% |
| 2018 Q3 | 3.6 Million USD | 1.28% |
| 2017 Q4 | 1.58 Million USD | -56.02% |
| 2017 Q3 | 3.6 Million USD | 4.75% |
| 2017 FY | 1.58 Million USD | -47.6% |
| 2017 Q1 | 3.16 Million USD | 4.78% |
| 2017 Q2 | 3.43 Million USD | 8.56% |
| 2016 Q1 | 2.29 Million USD | 74.04% |
| 2016 FY | 3.02 Million USD | 128.78% |
| 2016 Q4 | 3.02 Million USD | 34.7% |
| 2016 Q3 | 2.24 Million USD | -18.21% |
| 2016 Q2 | 2.74 Million USD | 19.31% |
| 2015 FY | 1.32 Million USD | 0.0% |
| 2015 Q4 | 1.32 Million USD | 42.08% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | 899.87 Thousand USD | 0.0% |
| 2015 Q3 | 930.01 Thousand USD | 3.35% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q1 | - USD | -100.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 FY | 261.4 Thousand USD | -93.94% |
| 2013 Q3 | 4.76 Million USD | 6.72% |
| 2013 Q1 | 4.41 Million USD | 2.3% |
| 2013 Q2 | 4.46 Million USD | 1.18% |
| 2013 Q4 | 261.4 Thousand USD | -94.51% |
| 2012 Q2 | 3.85 Million USD | 1.97% |
| 2012 Q3 | 4.16 Million USD | 8.11% |
| 2012 Q1 | 3.78 Million USD | 6.34% |
| 2012 Q4 | 4.31 Million USD | 3.51% |
| 2012 FY | 4.31 Million USD | 21.35% |
| 2011 FY | 3.55 Million USD | -8.25% |
| 2011 Q4 | 3.55 Million USD | 5.44% |
| 2011 Q1 | 4.26 Million USD | 9.99% |
| 2011 Q2 | 3.38 Million USD | -20.6% |
| 2011 Q3 | 3.37 Million USD | -0.36% |
| 2010 Q4 | 3.87 Million USD | 23.55% |
| 2010 FY | 3.87 Million USD | 40.78% |
| 2010 Q1 | 2.94 Million USD | 6.94% |
| 2010 Q2 | 2.95 Million USD | 0.51% |
| 2010 Q3 | 3.13 Million USD | 6.01% |
| 2009 Q2 | 2.32 Million USD | -14.78% |
| 2009 Q3 | 2.62 Million USD | 12.75% |
| 2009 FY | 2.75 Million USD | 66.61% |
| 2009 Q1 | 2.73 Million USD | 65.48% |
| 2009 Q4 | 2.75 Million USD | 4.79% |
| 2008 Q4 | 1.65 Million USD | -0.46% |
| 2008 FY | 1.65 Million USD | -27.87% |
| 2008 Q1 | 1.67 Million USD | -26.88% |
| 2008 Q2 | 1.55 Million USD | -7.39% |
| 2008 Q3 | 1.65 Million USD | 7.0% |
| 2007 Q3 | 27.34 Thousand USD | 7.21% |
| 2007 Q4 | 2.29 Million USD | 8276.57% |
| 2007 FY | 2.29 Million USD | 2503.36% |
| 2007 Q1 | 56.69 Thousand USD | -35.56% |
| 2007 Q2 | 25.5 Thousand USD | -55.02% |
| 2006 FY | 87.97 Thousand USD | -57.77% |
| 2006 Q1 | 178.97 Thousand USD | -14.1% |
| 2006 Q2 | 156.45 Thousand USD | -12.58% |
| 2006 Q3 | 124.45 Thousand USD | -20.45% |
| 2006 Q4 | 87.97 Thousand USD | -29.31% |
| 2005 Q2 | 249.57 Thousand USD | -10.21% |
| 2005 Q3 | 235.95 Thousand USD | -5.46% |
| 2005 Q4 | 208.34 Thousand USD | -11.7% |
| 2005 FY | 208.34 Thousand USD | -31.54% |
| 2005 Q1 | 277.95 Thousand USD | -8.67% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q3 | 312.69 Thousand USD | 0.0% |
| 2004 Q4 | 304.32 Thousand USD | -2.68% |
| 2004 FY | 304.32 Thousand USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.24 Million USD | 19.639% |
| Arrayit Corporation | 1.07 Million USD | -66.958% |
| Atlantic International Corp. | 2.93 Million USD | 38.574% |
| Biocept, Inc. | 12.1 Million USD | 85.134% |
| Bioqual, Inc. | 3.58 Million USD | 49.816% |
| CardioGenics Holdings Inc | 72.61 Thousand USD | -2378.975% |
| DermTech, Inc. | 54.39 Million USD | 96.691% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 471.86 Million USD | 99.619% |
| HTG Molecular Diagnostics, Inc. | 4.83 Million USD | 62.762% |
| iMD Companies, Inc. | 1.12 Million USD | -60.7% |
| IDenta Corp. | 789.14 Thousand USD | -128.105% |
| Interpace Biosciences, Inc. | 11.19 Million USD | 83.916% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | 43.84 Thousand USD | -4005.56% |
| Lumos Diagnostics Holdings Limited | 8.04 Million USD | 77.625% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 3.82 Million USD | 52.95% |
| NovelStem International Corp. | 3.57 Million USD | 49.642% |
| Optigenex Inc. | 8.94 Million USD | 79.867% |
| PharmChem, Inc. | 77.35 Thousand USD | -2227.102% |
| Proteome Sciences plc | 17.15 Million USD | 89.506% |
| Response Genetics, Inc | 6.37 Million USD | 71.755% |
| Rennova Health, Inc. | 15.32 Million USD | 88.257% |
| RushNet, Inc. | 4.82 Million USD | 62.678% |
| ScreenPro Security Inc. | 207.03 Thousand USD | -769.463% |
| Stella Diagnostics Inc. | 6.2 Million USD | 70.97% |
| Todos Medical Ltd. | 38.34 Million USD | 95.306% |